Search Within

Maria Lia Palomba

Formats
  1. Meeting Abstract (289)
  2. Journal Article (127)
  3. Research Letter (10)
  4. Review (8)
  5. Correspondence (3)
  6. Editorial (3)
  7. Book Section (1)
  8. Conference Paper (1)
  9. Guidelines (1)
Groups
  1. Center for Hematologic Malignancies (443)
  2. Department of Medicine (443)
  3. Hematologic Malignancies, Division of (443)
  4. Lymphoma (443)
  5. Survivorship Research (205)
  6. Sloan Kettering Institute Postdocs (155)

More Groups

People
  1. Andrew Zelenetz (140)
  2. Ariela Noy (129)
  3. Paul Hamlin (123)
  4. Gilles Salles (109)
  5. Gunjan Shah (109)
  6. Steven Horwitz (109)

More People

Years
  1. 2025 (15)
  2. 2024 (57)
  3. 2023 (69)
  4. 2022 (39)
  5. 2021 (41)
  6. 2020 (43)

More Years

Publications
  1. Blood (186)
  2. Journal of Clinical Oncology (37)
  3. Hematological Oncology (30)
  4. Blood Advances (19)
  5. British Journal of Haematology (14)
  6. Blood Cancer Journal (13)

More Publications

Publishers
  1. American Society of Hematology (206)
  2. Elsevier Inc. (44)
  3. American Society of Clinical Oncology (38)
  4. Nature Publishing Group (31)
  5. Wiley Blackwell (31)
  6. John Wiley & Sons (14)

More Publishers

Results (443)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment patterns and outcomes following progression of disease post-CAR-T therapy in relapsed or refractory mantle cell lymphoma: A multicenter analysis
    Meeting Abstract

    Epstein-Peterson, Z. D.; Lionel, A. C.; Joseph, A.; Drill, E.; Atallah-Yunes, S. A.; Brooks, T. R.; Chong, E. A.; Chong, E. R.; Dela Cruz, J.; Frank, M. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed/refractory Hodgkin lymphoma
    Meeting Abstract

    Stuver, R.; Vardhana, S. A.; Ganesan, N.; Boardman, A. P.; Caron, P.; Chang, T.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of broad-spectrum antibiotic exposure on CAR-T therapy outcomes in B-cell lymphoma: A multicenter international study
    Meeting Abstract

    Shouval, R.; Fei, T.; Gabrielli, G.; Smith, N. G.; Ghilardi, G.; Slingerland, J.; Peled, J. U.; Taur, Y.; Nasta, S. D.; Luna, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Site-specific responses and extranodal involvement implications in large B-cell lymphomas treated with CD19-CART therapy
    Meeting Abstract

    Luna de Abia, A.; Devlin, S. M.; Flynn, J.; Corona De Lapuerta, M.; Luttwak, E.; Landego, I.; Dahi, P. B.; Lin, R. J.; Parascondola, A.; Palomba, M. L.; more...
    Bone Marrow Transplantation (2024)

    Fulltext@MSK | Save
  • TRANSCEND FL: Phase 2 study results of lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL)
    Meeting Abstract

    Borchmann, P.; Morschhauser, F.; Dahiya, S.; Palomba, M. L.; García-Sancho, A. M.; Ortega, J. L. R.; Kuruvilla, J.; Jäger, U.; Cartron, G.; Izutsu, K.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Central nervous system bridging radiotherapy (CNS-BRT) achieves rapid cytoreduction prior to car T-cell therapy for aggressive B-cell lymphomas
    Meeting Abstract

    Cederquist, G.; Schefflein, J.; Devlin, S.; Shah, G.; Shouval, R.; Hubbeling, H.; Tringale, K.; Fregonese, B.; Hajj, C.; Boardman, A.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • A proof-of-principle study of split-course bridging radiotherapy (SC-BRT) prior to commercial CAR T-cell therapies for relapsed or refractory B-cell lymphomas: Results from phase 1a pilot cohort
    Meeting Abstract

    Imber, B. S.; Palomba, M. L.; Brosoff, A.; Roszak, E.; McAvoy, D.; Hosszu, K.; Boardman, A.; Dahi, P. B.; Lin, R. J.; Shah, G. L.; more...
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • Improvement in radiomic features following bridging therapy is prognostic for CD19 chimeric antigen receptor (CAR) T-cell therapy outcome
    Meeting Abstract

    Hubbeling, H. G.; Leithner, D.; Silverman, E. A.; Flynn, J.; Devlin, S.; Shah, G. L.; Fregonese, B.; Bedmutha, A.; Boardman, A.; Dahi, P. B.; more...
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • T-cell-based therapies for treating relapsed or refractory mantle cell lymphoma
    Review

    Epstein-Peterson, Z. D.; Palomba, M. L.
    Hematology-American Society of Hematology Education Program (2024)

    Fulltext@MSK | Save
  • ERK1/2 pro-survival signalling is suppressed by pirtobrutinib in ibrutinib-resistant MYD88-mutated lymphoma cells
    Journal Article

    Munshi, M.; Liu, X.; Kofides, A.; Tsakmaklis, N.; Hunter, Z. R.; Guerrera, M. L.; Canning, A.; Gustine, J. N.; Liu, S.; Hatcher, J. M.; more...
    British Journal of Haematology (2024)

    Fulltext@MSK | Save